Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b combination study of Tazemetostat with Tecentriq (atezolizumab) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Next Previous
Trial Profile

Phase 1b combination study of Tazemetostat with Tecentriq (atezolizumab) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tazemetostat (Primary) ; Atezolizumab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Genentech

Most Recent Events

  • 08 May 2018 This trial has enrolled 45 patients with DLBCL till date, according to an Epizyme media release.
  • 09 Mar 2017 According to an Epizyme media release, company expects the optimal dose will be established this year.
  • 03 Nov 2016 According to an Epizyme media release, status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top